These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 8088411)
1. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Hongo A; Seki S; Akiyama K; Kudo T Int J Biochem; 1994 Aug; 26(8):1009-16. PubMed ID: 8088411 [TBL] [Abstract][Full Text] [Related]
2. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ; Friedlos F; Lydall DA; Roberts JJ Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [TBL] [Abstract][Full Text] [Related]
3. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137 [TBL] [Abstract][Full Text] [Related]
4. Detection and analyses by gel electrophoresis of cisplatin-mediated DNA damage. Zhang B; Seki S; Akiyama K; Tsutsui K; Li T; Nagao K Acta Med Okayama; 1992 Dec; 46(6):427-34. PubMed ID: 1336637 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion? Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150 [TBL] [Abstract][Full Text] [Related]
6. Protein interactions with platinum-DNA adducts: from structure to function. Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816 [TBL] [Abstract][Full Text] [Related]
7. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Los G; van Vugt MJ; den Engelse L; Pinedo HM Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374 [TBL] [Abstract][Full Text] [Related]
8. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622 [TBL] [Abstract][Full Text] [Related]
10. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137 [TBL] [Abstract][Full Text] [Related]
11. Escherichia coli DNA polymerase I: inherent exonuclease activities differentiate between monofunctional and bifunctional adducts of DNA and cis- or trans-diamminedichloroplatinum(II). An exonuclease investigation of the kinetics of the adduct formation. Bernges F; Dörner G; Holler E Eur J Biochem; 1990 Aug; 191(3):743-53. PubMed ID: 2167853 [TBL] [Abstract][Full Text] [Related]
12. Enhanced formation of reactive species from cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals. Tonetti M; Giovine M; Gasparini A; Benatti U; De Flora A Biochem Pharmacol; 1993 Oct; 46(8):1377-83. PubMed ID: 8240386 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Reed E; Gupta-Burt S; Litterst CL; Poirier MC Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937 [TBL] [Abstract][Full Text] [Related]
14. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117 [TBL] [Abstract][Full Text] [Related]
15. Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Burstyn JN; Heiger-Bernays WJ; Cohen SM; Lippard SJ Nucleic Acids Res; 2000 Nov; 28(21):4237-43. PubMed ID: 11058123 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of cisplatin-mediated DNA damage in vitro by ribonucleotides. Seki S; Hongo A; Zhang B; Akiyama K; Sarker AH; Kudo T Jpn J Cancer Res; 1993 Apr; 84(4):462-7. PubMed ID: 8390426 [TBL] [Abstract][Full Text] [Related]
17. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA. Payet D; Gaucheron F; Sip M; Leng M Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343 [TBL] [Abstract][Full Text] [Related]
18. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228 [TBL] [Abstract][Full Text] [Related]
20. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons. Rezaee M; Hunting DJ; Sanche L Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):847-53. PubMed ID: 23910707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]